

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 17343

**Title:** The use of entecavir in HBV reactivation of a patient with non-Hodgkin's lymphoma

**Reviewer's code:** 02941980

**Reviewer's country:** China

**Science editor:** Jing Yu

**Date sent for review:** 2015-03-04 17:12

**Date reviewed:** 2015-04-02 21:34

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

Dear authors: The article "The use of entecavir in HBV reactivation of a patient with non-Hodgkin's lymphoma" shows some additional comments on this case report by Lui et al. I agree with the opinions of him that the resolution of HBV reactivation might be achieved with lamivudine instead of entecavir or also be observed when entecavir was used at a dose of 0.5 mg. These comments may provide practical value for antiviral prophylaxis against hepatitis B. Thank you and best regards. Zhijun Su